SOURCE: Geneart AG

October 11, 2007 05:26 ET

GENEART is again Recognized as a German Top-Flight "Technology Fast 50" Company

REGENSBURG, GERMANY--(Marketwire - October 11, 2007) -



- GENEART AG among the top 30 fastest growing technology companies in Germany for the third time running

- 2nd rank among life science companies

- Cumulative growth by more than 500 percent in the last five years

- Synthetic genes mature from niche market product to standard applications

Regensburg, October 11, 2007 - The GENEART AG with its above average sales growth ranks 21st among the fastest growing German technology companies in the "Technology Fast 50" competition. Creator and organizer of the competition is the auditing and advisory services firm Deloitte. Yesterday evening, the 50 winners of the prize for the fastest growing technology enterprises showcased their business in Frankfurt (Germany). The competition was attended by German technology companies from business sectors including communications/ networking, the Internet, semiconductors/ equipment, computers/ peripherals, the life sciences and software. The placements are based on the cumulative sales growth in percent for the preceding consecutive five years.

The publicly traded GENEART AG as the global leader in the production of synthetic genes and synthetic biology specialist grew its sales by more than 500 percent to EURO 7.8M in this five-year period, achieving one of the best placements among German companies together with Q-Cells, QSC and proventis. Among life science companies GENEART ranks 2nd in the competition.

"Step by step, the synthetic gene technology has gained wide market acceptance. Clearly, the production of synthetic genes in general and the GENEART technology platform for gene synthesis in particular have well surpassed the traditional methods in molecular biology, and the new procedures have cleared the way to a much faster and more cost-effective access to genes, the blueprints of life. The use of these genes can drastically shorten the development times for many drugs, vaccines or industrial enzymes. Moreover, our technology platform offers our customers unlimited design flexibilities and thus supports researchers in their quest for products with improved attributes", points out Professor Ralf Wagner, CSO of the GENEART AG.

Background: In the past, scientists had to spent months of hard work in the laboratory to e.g. isolate a gene from a virus for their R&D projects. The GENEART technology eliminates the above described work. GENEART needs nothing but the electronic gene sequence information to synthesize the desired gene in just a few days. This turns the GENEART technology into a crucial advantage, especially in light of the modern methods of sequencing and analyzing genes, which have already produced a formidable wealth of known gene sequences, as demonstrated by the genome project HUGO (Human Genome Organization). This treasure box of information used to be of only limited use, since it remained difficult to get a handle on the real gene sequences using only the conventional tools of molecular biology. In the last ten years, this has created an ever widening gap between conventionally isolated genes and the rapidly accumulating wealth of available gene sequence information. GENEART closes this gap with new industrial processes for the production of genes based solely on electronically available sequence information. This production of defined synthetic genes is not only fast but also cost-efficient.

Other Advantages: GENEART has developed proprietary software to visualize the targeted modification of gene sequences on a computer monitor, much like changing images using a Photoshop program. This enables scientists to optimize genes for a specific design goal. The benefits for the customer include improved product attributes, higher production rates, enhanced efficacies and lower production costs.

"Meanwhile, many companies and research institutes have recognized the benefits of the GENEART services. Almost all of the largest global pharmaceutical companies, many international biotechnology companies, renowned universities and large research facilities now use the GENEART technology platform", notes Christian Ehl, CFO of the GENEART AG.


For further inquiries, please contact:

Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
D-93053 Regensburg
Germany
Phone: +49-(0)941-942 76 - 638
Fax: +49-(0)941-942 76 - 711
ir@geneart.com
www.geneart.com

Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.

About GENEART AG

In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 140 people. Since May 2006, GENEART is listed on the German Stock Exchange.

About Deloitte in Germany

Deloitte is one of the leading auditing and consulting firms in Germany. The firm's broad service spectrum includes auditing, tax accounting, consulting and corporate finance consulting. 3,400 Deloitte employees in 18 branch offices serve companies and institutions of any size or legal form in all sectors of the economy. Deloitte looks back at almost 100 years of service history. 135,000 employees in almost 150 countries on the globe represent Deloitte via the Deloitte Touche Tohmatsu network.

Deloitte refers to Deloitte Touche Tohmatsu, an association formed according to the Swiss Civil Code, and its member companies including the affiliates of these member companies. Neither Deloitte Touche Tohmatsu as an association under the Swiss Civil Code nor its member companies are liable or responsible for each other's actions or omissions. Each member company is a legally separate and independent entity, whether or not it operates under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or another name associated with the aforementioned names. Services are rendered by each of the individual member companies and not by the Association Deloitte Touche Tohmatsu. Copyright © 2006 Deloitte & Touche GmbH Wirtschaftsprüfungsgesellschaft (Deloitte & Touche GmbH [LLC according to Swiss law], Auditing Firm). All rights reserved.

GENEART is again Recognized as a German Top-Flight "Technology Fast 50" Company: http://hugin.info/136633/R/1159343/224581.pdf

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information